Good-Heart6425
Explorer
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial #-boehringer-zealand-drug-leads-to-16-6-weight-loss-in-late-stage-trial Reuters 2:00 AM ET Apr-28-2026
FRANKFURT, April 28 (Reuters) - Boehringer Ingelheim announced on Tuesday that its experimental obesity treatment produced an average weight reduction of up to 16.6% in a late-stage trial, as the privately held German pharmaceutical company aims to close the gap with obesity drug leaders Eli Lilly (LLY.NaE) and Novo Nordisk.
According to a company statement, the Phase III trial found that patients receiving survodutide shed 16.6% of their body weight after 76 weeks, versus 3.2% among those given a placebo.
The study enrolled adults who were obese or overweight and did not have type 2 diabetes.
Boehringer obtained the rights in 2011 to exclusively develop and commercialise survodutide from Denmark's Zealand Pharma, which is eligible for royalty payments on worldwide sales.
Complete findings from the Phase III trial, known as SYNCHRONIZE-1, will be shared at the American Diabetes Association's 2026 Scientific Sessions, taking place from June 5 to June 8, 2026.
Survodutide imitates the appetite-suppressing gut hormone GLP-1, which is the target of injectable drugs like Novo's Wegovy, while also mimicking the gut hormone glucagon—a dual approach some developers believe could enhance weight loss. Altimmune (ALT.NaE) is working on a drug that leverages the effects of these same two hormones. In early 2024, survodutide showed encouraging mid-stage results for treating fatty liver, also referred to as metabolic-dysfunction-associated steatohepatitis, or MASH. (Reporting by Patricia Weiss. Writing by Ludwig Burger. Editing by Mark Potter)
FRANKFURT, April 28 (Reuters) - Boehringer Ingelheim announced on Tuesday that its experimental obesity treatment produced an average weight reduction of up to 16.6% in a late-stage trial, as the privately held German pharmaceutical company aims to close the gap with obesity drug leaders Eli Lilly (LLY.NaE) and Novo Nordisk.
According to a company statement, the Phase III trial found that patients receiving survodutide shed 16.6% of their body weight after 76 weeks, versus 3.2% among those given a placebo.
The study enrolled adults who were obese or overweight and did not have type 2 diabetes.
Boehringer obtained the rights in 2011 to exclusively develop and commercialise survodutide from Denmark's Zealand Pharma, which is eligible for royalty payments on worldwide sales.
Complete findings from the Phase III trial, known as SYNCHRONIZE-1, will be shared at the American Diabetes Association's 2026 Scientific Sessions, taking place from June 5 to June 8, 2026.
Survodutide imitates the appetite-suppressing gut hormone GLP-1, which is the target of injectable drugs like Novo's Wegovy, while also mimicking the gut hormone glucagon—a dual approach some developers believe could enhance weight loss. Altimmune (ALT.NaE) is working on a drug that leverages the effects of these same two hormones. In early 2024, survodutide showed encouraging mid-stage results for treating fatty liver, also referred to as metabolic-dysfunction-associated steatohepatitis, or MASH. (Reporting by Patricia Weiss. Writing by Ludwig Burger. Editing by Mark Potter)
